CA3100848A1 - Procedes d'attenuation de maladies et de troubles neurologiques - Google Patents

Procedes d'attenuation de maladies et de troubles neurologiques Download PDF

Info

Publication number
CA3100848A1
CA3100848A1 CA3100848A CA3100848A CA3100848A1 CA 3100848 A1 CA3100848 A1 CA 3100848A1 CA 3100848 A CA3100848 A CA 3100848A CA 3100848 A CA3100848 A CA 3100848A CA 3100848 A1 CA3100848 A1 CA 3100848A1
Authority
CA
Canada
Prior art keywords
patient
neurodegenerative disease
disease
cognitive function
pabra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3100848A
Other languages
English (en)
Inventor
Anthony P. FORD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curasen Therapeutics Inc
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of CA3100848A1 publication Critical patent/CA3100848A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dans divers aspects et modes de réalisation, l'invention concerne des compositions et des procédés pour améliorer la cognition et/ou traiter une maladie neurodégénérative chez un patient. Dans certains modes de réalisation, les compositions et les procédés comprennent l'identification d'un patient nécessitant ou souhaitant une amélioration de la fonction cognitive et/ou le traitement d'une maladie neurodégénérative, et l'administration au patient d'un ß-agoniste et éventuellement d'un ß-bloquant à action périphérique (PABRA).
CA3100848A 2018-06-14 2019-06-14 Procedes d'attenuation de maladies et de troubles neurologiques Pending CA3100848A1 (fr)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862685246P 2018-06-14 2018-06-14
US201862685249P 2018-06-14 2018-06-14
US201862685247P 2018-06-14 2018-06-14
US62/685,247 2018-06-14
US62/685,249 2018-06-14
US62/685,246 2018-06-14
US201862686660P 2018-06-18 2018-06-18
US201862686663P 2018-06-18 2018-06-18
US201862686658P 2018-06-18 2018-06-18
US62/686,660 2018-06-18
US62/686,663 2018-06-18
US62/686,658 2018-06-18
US201962825702P 2019-03-28 2019-03-28
US201962825675P 2019-03-28 2019-03-28
US201962825670P 2019-03-28 2019-03-28
US201962825571P 2019-03-28 2019-03-28
US62/825,702 2019-03-28
US62/825,670 2019-03-28
US62/825,571 2019-03-28
US62/825,675 2019-03-28
PCT/US2019/037358 WO2019241736A1 (fr) 2018-06-14 2019-06-14 Procédés d'atténuation de maladies et de troubles neurologiques

Publications (1)

Publication Number Publication Date
CA3100848A1 true CA3100848A1 (fr) 2019-12-19

Family

ID=68842342

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3100848A Pending CA3100848A1 (fr) 2018-06-14 2019-06-14 Procedes d'attenuation de maladies et de troubles neurologiques

Country Status (5)

Country Link
EP (1) EP3806847A4 (fr)
JP (1) JP2021527711A (fr)
AU (1) AU2019287771A1 (fr)
CA (1) CA3100848A1 (fr)
WO (1) WO2019241736A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051305A1 (fr) * 2020-09-01 2022-03-10 Curasen Therapeutics, Inc. Compositions et méthodes de soulagement d'affections et de troubles neurologiques
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (fr) 2023-01-20 2025-11-26 Atrogi AB Agonistes du récepteur bêta 2-adrénergique pour le traitement ou la prévention de l'atrophie musculaire
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (fr) 2024-05-17 2025-11-20 Atrogi Ab UTILISATION D'AGONISTES DU RÉCEPTEUR β2-ADRÉNERGIQUE DANS LE TRAITEMENT DE L'ATROPHIE MUSCULAIRE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
WO2011133226A2 (fr) * 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Procédé d'amélioration de troubles de l'apprentissage et de la mémoire dus à des maladies neurodégénératives, et composés et compositions pour ces mêmes fins
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2014210544A2 (fr) * 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Antagonistes d'adrénorécepteurs pour la prévention et le traitement d'affections neurodégénératives

Also Published As

Publication number Publication date
EP3806847A4 (fr) 2022-05-04
AU2019287771A1 (en) 2021-01-28
JP2021527711A (ja) 2021-10-14
WO2019241736A1 (fr) 2019-12-19
EP3806847A1 (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
US12558325B2 (en) Methods for improving neurological diseases and disorders
CA3100697A1 (fr) Procedes de diagnostic, de surveillance et de traitement de maladies et de troubles neurologiques
CA3100848A1 (fr) Procedes d'attenuation de maladies et de troubles neurologiques
US20230263749A1 (en) Compositions and methods for improving neurological diseases and disorders
WO2009005509A1 (fr) Colorants analogues d'éther phospholipidique utilisant la fluorescence dans la région du proche infrarouge dans des applications endoscopiques
JP2011148793A (ja) 経鼻中枢神経系組織標識用組成物、経鼻中枢神経系組織標識用組成物を用いた標識方法及びスクリーニング方法
ES2750839T3 (es) Composición farmacéutica para la prevención, tratamiento o retraso de la enfermedad de Alzheimer o demencia que contiene agente receptor acoplado a proteína G 19 como ingrediente activo
US20250134835A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
US20210251923A1 (en) Methods for improving neurological diseases and disorders
US12616667B2 (en) Compositions and methods for improving neurological diseases and disorders
US20230157974A1 (en) Compositions and methods for improving neurological diseases and disorders
US20230097883A1 (en) Ergothioneine pet compounds and methods of use thereof
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
US7081238B2 (en) Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
WO2024137478A1 (fr) Méthpdes de traitement de divers états pathologiques et indications avec des agonistes et des antagonistes
WO2025188807A1 (fr) Compositions combinées et procédés d'utilisation
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
Micou et al. High-speed optical mapping of heart and brain voltage activities in zebrafish larvae exposed to environmental contaminants
KR20170138437A (ko) 신경질환 치료용 푸마레이트를 정맥투여하는 방법 및 조성물
WO2024137506A1 (fr) Compositions et méthodes de soulagement de maladies et de troubles neurologiques
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
Leuzy In Vivo Quantification of Glutamatergic Abnormalities in Behavioral Variant Frontotemporal Dementia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220822